Delpor, Inc. (closely-held)

Delpor, Inc.
150 North Hill Drive, Suite 25
Brisbane, CA 94005
Phone: (415) 480-6870
https://delpor.com

Delpor, Inc. (“Delpor” or “the Company”) is a closely held clinical-stage biopharmaceutical company developing once-yearly therapeutic products to treat chronic conditions. The Company’s unique and patented Prozor™ technology facilitates the release of specific insoluble drugs, such as most antipsychotics, from a non-mechanical (passive) implantable drug delivery device (which is the length of a matchstick). This device is placed under the skin in the abdomen and employs a distinct formulation to allow for the consistent release of medications. The placement procedure for the device is brief, typically lasting only 10 minutes, and is conducted in a physician’s office under local anesthesia. This enhances medication adherence, efficacy, safety, treatment outcomes, and patient quality of life. Delpor’s clinical assets include a 6-12-month formulation of risperidone (DLP-114) for schizophrenia treatment as well as a 6-12-month formulation of naltrexone (DLP-160) for Opioid Use Disorder (OUD) and alcohol dependence treatment. Also in development are earlier stage preclinical candidates, with a 6-month drug formulation of tizanidine (DLP-208) for moderate to severe spasticity, as well as compounds for Parkinson’s, Alzheimer’s, and more. Delpor thinks of its technology as ‘a once-a-year cure for an incurable disease.’

* Updated on May 29, 2024.